Cargando…

Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study

INTRODUCTION: Because of the cost, in the hemodialysis centers of Kinshasa, the double dose of hepatitis B (HBV) vaccine is administered only to HIV infected patients while other patients receive a single dose. This study aimed to evaluate the single-dose vaccination Protocol and identify determinan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kengibe, Pitchou Yemasai, Makulo, Jean-Robert Risassy, Nlandu, Yannick Mayamba, Lepira, François Bompeka, Sumaili, Ernest Kiswaya, Bukabau, Justine Busanga, Mbendi, Charles Nlombi, Ahuka, Steve Mundeke, Tshimpi, Antoine Wola, Ngoma, Patrick Kisoko, Mangani, Nseka Nazaire, Mbendi, Sebastien Nsukini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906547/
https://www.ncbi.nlm.nih.gov/pubmed/33708291
http://dx.doi.org/10.11604/pamj.2019.34.122.19603
_version_ 1783655311903555584
author Kengibe, Pitchou Yemasai
Makulo, Jean-Robert Risassy
Nlandu, Yannick Mayamba
Lepira, François Bompeka
Sumaili, Ernest Kiswaya
Bukabau, Justine Busanga
Mbendi, Charles Nlombi
Ahuka, Steve Mundeke
Tshimpi, Antoine Wola
Ngoma, Patrick Kisoko
Mangani, Nseka Nazaire
Mbendi, Sebastien Nsukini
author_facet Kengibe, Pitchou Yemasai
Makulo, Jean-Robert Risassy
Nlandu, Yannick Mayamba
Lepira, François Bompeka
Sumaili, Ernest Kiswaya
Bukabau, Justine Busanga
Mbendi, Charles Nlombi
Ahuka, Steve Mundeke
Tshimpi, Antoine Wola
Ngoma, Patrick Kisoko
Mangani, Nseka Nazaire
Mbendi, Sebastien Nsukini
author_sort Kengibe, Pitchou Yemasai
collection PubMed
description INTRODUCTION: Because of the cost, in the hemodialysis centers of Kinshasa, the double dose of hepatitis B (HBV) vaccine is administered only to HIV infected patients while other patients receive a single dose. This study aimed to evaluate the single-dose vaccination Protocol and identify determinants of seroconversion's lack of anti-HBs after vaccination schedule. METHODS: 56 non-HIV chronic hemodialysis patients serologically negative for HBs Ag, anti-HBs and anti-HBc were selected between January 2014 and December 2016. The recombinant DNA vaccine (Euvax B(®)20 μg) was administered intramuscularly in the deltoid muscle at days 0, 30, 60 and 180. Serum anti-HBs titer was assayed at day 240. The endpoint was seroconversion, defined as anti-HBs titer ≥ 10 IU/l (10-99 IU/l = low protective vaccine response; ≥ 100 IU/l = highly protective vaccine response). Anti-HBs titer < 10 IU/l defined a lack of seroconversion. A Logistic regression model was used to identify factors associated with the lack of seroconversion. RESULTS: In the study group (mean age 55.6± 15.1 years; 73 % men, 36% diabetic and 86% hypertensive), low and highly protective vaccine responses were seen in 32% and 50% respectively versus 18% of patient had a lack of seroconversion. CRP > 6 mg/L (aOR: 8.96), hypoalbuminemia (aOR: 6.50) and KT/V < 1.2 (aOR: 3.70) were associated with the lack of seroconversion. CONCLUSION: Half of the patients in the study had either a lack or low protective vaccine response. Patient-related factors and hemodialysis parameters were the main factors associated with the lack of anti-HbS seroconversion. These results highlight the need to maximize doses of vaccine in all patients.
format Online
Article
Text
id pubmed-7906547
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-79065472021-03-10 Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study Kengibe, Pitchou Yemasai Makulo, Jean-Robert Risassy Nlandu, Yannick Mayamba Lepira, François Bompeka Sumaili, Ernest Kiswaya Bukabau, Justine Busanga Mbendi, Charles Nlombi Ahuka, Steve Mundeke Tshimpi, Antoine Wola Ngoma, Patrick Kisoko Mangani, Nseka Nazaire Mbendi, Sebastien Nsukini Pan Afr Med J Research INTRODUCTION: Because of the cost, in the hemodialysis centers of Kinshasa, the double dose of hepatitis B (HBV) vaccine is administered only to HIV infected patients while other patients receive a single dose. This study aimed to evaluate the single-dose vaccination Protocol and identify determinants of seroconversion's lack of anti-HBs after vaccination schedule. METHODS: 56 non-HIV chronic hemodialysis patients serologically negative for HBs Ag, anti-HBs and anti-HBc were selected between January 2014 and December 2016. The recombinant DNA vaccine (Euvax B(®)20 μg) was administered intramuscularly in the deltoid muscle at days 0, 30, 60 and 180. Serum anti-HBs titer was assayed at day 240. The endpoint was seroconversion, defined as anti-HBs titer ≥ 10 IU/l (10-99 IU/l = low protective vaccine response; ≥ 100 IU/l = highly protective vaccine response). Anti-HBs titer < 10 IU/l defined a lack of seroconversion. A Logistic regression model was used to identify factors associated with the lack of seroconversion. RESULTS: In the study group (mean age 55.6± 15.1 years; 73 % men, 36% diabetic and 86% hypertensive), low and highly protective vaccine responses were seen in 32% and 50% respectively versus 18% of patient had a lack of seroconversion. CRP > 6 mg/L (aOR: 8.96), hypoalbuminemia (aOR: 6.50) and KT/V < 1.2 (aOR: 3.70) were associated with the lack of seroconversion. CONCLUSION: Half of the patients in the study had either a lack or low protective vaccine response. Patient-related factors and hemodialysis parameters were the main factors associated with the lack of anti-HbS seroconversion. These results highlight the need to maximize doses of vaccine in all patients. The African Field Epidemiology Network 2019-10-31 /pmc/articles/PMC7906547/ /pubmed/33708291 http://dx.doi.org/10.11604/pamj.2019.34.122.19603 Text en © Pitchou Yemasai Kengibe et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kengibe, Pitchou Yemasai
Makulo, Jean-Robert Risassy
Nlandu, Yannick Mayamba
Lepira, François Bompeka
Sumaili, Ernest Kiswaya
Bukabau, Justine Busanga
Mbendi, Charles Nlombi
Ahuka, Steve Mundeke
Tshimpi, Antoine Wola
Ngoma, Patrick Kisoko
Mangani, Nseka Nazaire
Mbendi, Sebastien Nsukini
Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study
title Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study
title_full Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study
title_fullStr Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study
title_full_unstemmed Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study
title_short Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study
title_sort response to single dose hepatitis b vaccine in congolese non-hiv hemodialysis patients: a prospective observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906547/
https://www.ncbi.nlm.nih.gov/pubmed/33708291
http://dx.doi.org/10.11604/pamj.2019.34.122.19603
work_keys_str_mv AT kengibepitchouyemasai responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT makulojeanrobertrisassy responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT nlanduyannickmayamba responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT lepirafrancoisbompeka responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT sumailiernestkiswaya responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT bukabaujustinebusanga responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT mbendicharlesnlombi responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT ahukastevemundeke responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT tshimpiantoinewola responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT ngomapatrickkisoko responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT manganinsekanazaire responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy
AT mbendisebastiennsukini responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy